Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 92%
filed 2026-08-07
The Company entered into a Securities Purchase Agreement on August 7, 2026, establishing a $36 million commitment to fund pre-paid purchases over two years, with settlement through issuance of Class A Shares at 50% of market price (with a $0.10 floor). This is a dilutive equity issuance mechanism—a structured PIPE-like arrangement where the investor funds cash and the Company settles by issuing shares at a significant discount, creating substantial dilution to existing shareholders. The filing explicitly references a concurrent prospectus supplement for the offer and sale of Class A Shares.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
The 6-K discloses completion of a registered direct offering in which Nano-X sold 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants to a single institutional investor for approximately $8.0 million gross proceeds. This is a dilutive equity issuance under a registered shelf offering (Form F-3), meeting the definition of dilutive_issuance. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 3.02
The Company issued 537,335 shares of common stock in exchange for 1,252 shares of Series B Preferred Stock valued at $1,252,000. The issuance was unregistered and conducted under Section 3(a)(9) of the Securities Act. This represents a material dilutive equity issuance that would affect shareholder ownership and voting power, typical of the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The Company issued 779,371 shares of common stock to Lind Global Asset Management XII LLC in three tranches (July 14, July 16, and August 6, 2026) to satisfy payment and conversion obligations under senior secured convertible promissory notes. The issuance was made in reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration that signal a private placement to an existing securityholder. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of share ownership and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
The 6-K discloses a Securities Purchase Agreement dated August 7, 2026, under which Fusion Fuel Green PLC agreed to issue 431,367 Class A ordinary shares, pre-funded warrants, and common warrants for approximately $1,550,000 in gross proceeds. This is a classic private placement (PIPE) transaction conducted under Section 4(a)(2) and Regulation D Rule 506(b), involving unregistered equity issuance with warrant coverage that creates substantial dilution to existing shareholders. The company must register the resale securities on Form F-3 within 90 days and maintain effectiveness, with penalties for non-compliance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
EX-99.1
The exhibit discloses completion of an underwritten public offering of 1,715,000 common shares at US$4.00 per share for aggregate gross proceeds of US$6.9 million, including participation by strategic investor Uranium Energy Corp. through its subsidiary. This is a material dilutive equity issuance that increases the share count and raises capital, with Uranium Energy's participation increasing its ownership from approximately 32.2% to 32.6% on a non-diluted basis.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Diginex disclosed a private placement of 20 million ordinary shares and 20 million warrants for $20 million, signed on July 20, 2026 with three unrelated investors. The offering was conducted under Section 4(a)(2) and Regulation D/S exemptions. This is a material dilutive equity issuance that raises capital and significantly increases share count, affecting existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
On August 3, 2026, Ares Real Estate Income Trust Inc. completed an unregistered private placement under Regulation D, issuing 1,168,737 Class S-PR shares ($9.68M) and 1,727,341 Class I-PR shares ($14.20M) for gross proceeds of approximately $23.9M.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
EX-99.1
The press release announces a registered direct offering of 1,428,572 Class A ordinary shares and pre-funded warrants for $5.0 million gross proceeds at $3.50 per share. This is a dilutive equity issuance registered under Form F-3, representing new equity capital raised through the sale of registered securities to an institutional investor, which materially affects shareholder ownership and is a key financing event for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $33.7 million across four classes of common stock on August 3, 2026, exempt from registration under Section 4(a)(2). This is a classic dilutive issuance event, particularly material given the aggregate consideration and the inclusion of shares issued to the investment adviser (Invesco Advisers, Inc.) as payment for management fees, which would affect existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
Scholar Rock filed a prospectus supplement on August 6, 2026 to offer and sell up to $200 million in additional shares of common stock through an at-the-market (ATM) offering program. This is a registered equity issuance that will dilute existing shareholders and represents a material capital-raising event. The company has already raised approximately $257.7 million under the ATM Program, and this new prospectus supplement authorizes an additional $200 million in offerings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
The filing discloses the underwriters' exercise of an option to purchase an additional 2,250,000 shares of common stock in a registered public offering, generating approximately $312.2 million in net proceeds. This represents a dilutive equity issuance that increases shares outstanding and would materially affect a reasonable investor's assessment of ownership dilution and capital structure, even though it is a registered offering rather than a private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Clearway Energy entered into an Equity Distribution Agreement (ATM Program) with major investment banks to offer and sell up to $100 million of Class C common stock at market prices. This at-the-market offering is a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Clearway Energy, Inc. entered into an Equity Distribution Agreement (ATM Program) on August 6, 2026, authorizing the sale of up to $100 million in Class C common stock through multiple investment banks. This is a classic at-the-market (ATM) offering—an unregistered or registered equity issuance program that creates potential dilution to existing shareholders. The filing explicitly references the prospectus supplement and shelf registration statement (Form S-3), confirming this is a registered direct offering of equity securities. Such capital-raising activities are material to investors assessing the company's financing strategy and shareholder dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock "from time to time at the Company's sole discretion" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Innodata entered into an equity distribution agreement with multiple sales agents to offer and sell up to $300 million in common stock shares through an "at the market offering" under a newly filed Form S-3 shelf registration. This is a dilutive equity issuance that creates potential for substantial shareholder dilution and capital raising, which materially affects investor assessment of the company's capital structure and financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-08-06
Item 1.01
LTC Properties terminated its prior at-the-market equity distribution agreement and entered into a new Equity Distribution Agreement on August 6, 2026, permitting the issuance and sale of up to $500 million of common stock through sales agents and forward sale agreements. The company intends to use proceeds to pay down debt, fund acquisitions, and support working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The unregistered securities were sold under Section 4(a)(2) of the Securities Act and Rule 506, with 90-day lock-up restrictions, representing a material dilutive issuance to raise capital for the company's operations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-08-06
Item 1.01
Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. The pre-funded warrants are immediately exercisable and represent a material dilutive issuance of equity securities that increases the company's outstanding share count.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
CG Oncology filed Amendment No. 2 to its prospectus on August 6, 2026, increasing the shares available for sale under an Open Market Sale Agreement (ATM offering) with Jefferies LLC by an additional $500 million, following prior $550 million in sales.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses unregistered sales of equity securities totaling approximately $25.1 million across multiple tranches (June 1, July 1, and August 3, 2026) to accredited investors under Section 4(a)(2) and Regulation D exemptions. These private placements of common shares of beneficial interest represent dilutive equity issuances material to the fund's capital structure and investor base.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses an unregistered sale of 767,565 common shares for approximately $15.98 million under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance in a continuous private offering, material to investors as it increases share count and dilutes existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million, allowing the company to sell an additional $213 million in shares through an unregistered equity program.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-06
Apple Hospitality REIT amended its equity distribution agreement on August 6, 2026, to continue selling up to $500 million of common shares through multiple agents. While the amendment itself is primarily administrative (updating agent definitions), the underlying equity distribution program represents a material dilutive issuance arrangement that allows the company to raise capital through at-the-market or negotiated offerings. This is material to investors as it signals the company's capital-raising strategy and potential dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
TCGX Acquisition Corp. completed an unregistered private placement of 522,500 Class A ordinary shares at $10.00 per share ($5.225 million aggregate) to the Sponsor and Jefferies LLC, executed simultaneously with the IPO closing pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Organogenesis entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026, authorizing the sale of up to $75 million in Class A common stock through agents BTIG and Citizens JMP Securities. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a common capital-raising mechanism at small- and mid-cap issuers. The material amount ($75M) and the explicit authorization to sell shares "from time to time" through registered agents make this a dilutive issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
The Company filed a prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC. This represents a material dilutive equity issuance under an ATM (at-the-market) offering program, with the Company having already issued $85.0 million in shares under the prior prospectus supplement. The filing of a new prospectus supplement to increase the offering capacity signals a significant capital raise that would materially dilute existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-06
EX-99.1
This press release announces a registered direct offering of 8 million ordinary shares and 8 million warrants at $1.00 per unit, raising approximately $8 million gross proceeds. The offering is a registered direct placement under the company's Form F-3 shelf registration, representing a dilutive equity issuance to a single institutional investor. The warrant component (exercisable at $1.15, expiring five years from closing) adds further dilution potential. This is a material capital-raising event for a medical imaging company with acknowledged going-concern risks mentioned in the forward-looking statements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The Company issued 426,848 shares of Common Stock (with an additional 5,184 shares pending issuance) to satisfy an earn-out obligation under the Prevu acquisition merger agreement. The shares were issued pursuant to Section 4(a)(2) and Rule 506 of Regulation D as an unregistered private placement to accredited investors. This is a classic dilutive issuance under Item 3.02, representing a material increase in share count (approximately 7.3% dilution based on the post-issuance outstanding count of 5,861,724 shares) and a direct financial obligation satisfied through equity rather than cash.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-06
EX-99.1
The news release announces final TSX Venture Exchange approval and receipt of funds from a "non-brokered private placement" previously disclosed on July 16, 2026. Non-brokered private placements are unregistered equity issuances that dilute existing shareholders. The announcement confirms completion of the offering and receipt of proceeds, making this a material capital-raising event typical of small-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities on August 6, 2026, authorizing the sale of up to $75 million in common stock through an "at the market" offering under Rule 415. This is a dilutive equity issuance that provides the company with a capital-raising mechanism and would materially affect existing shareholders through potential dilution. The substantial offering size and explicit authorization to sell shares make this a material capital event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-06
Item 2.03
Item 2.03 discloses an issuance of shares relying on Section 4(a)(2) exemption (private placement), with restricted legend shares issued to sophisticated investors with no general solicitation. The disclosure of unregistered equity issuance under Item 2.03 is characteristic of dilutive private placements, which are material events affecting shareholder equity and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02 discloses an unregistered sale of 251,666 shares of common stock to White Lion Capital, LLC at prices ranging from $2.79 to $2.90 per share for approximately $716,000 in gross proceeds. The shares were issued under Section 4(a)(2) exemption, which is a classic private placement structure. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses an unregistered sale of 92,960.33 common shares across multiple classes for approximately $1.895 million on August 3, 2026, exempt under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities to third-party investors, directly matching the Item 3.02 disclosure requirement and the dilutive_issuance event type. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
Silvaco issued conversion shares underlying the $10.0 million convertible note in a private placement under Section 4(a)(2) exemption, with the securities offered and sold as unregistered securities creating potential equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-06
Item 3.02
On July 31, 2026, Valion Bio entered into a Securities Purchase Agreement with Statera and Avenue Venture Opportunities Fund, issuing 1,287.8685 shares of Series A Preferred Stock as consideration for a Milestone Payment. The shares are unregistered, restricted securities issued under Section 4(a)(2) and Regulation D exemptions to accredited investors, materially diluting existing shareholder ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-06
Item 1.01
UWM entered into a securities purchase agreement on August 5, 2026, issuing 1.65 billion warrants (Class A and Class B) plus 1.5 million Series A-1 and 150,000 Series A-2 preferred shares for $1.65 billion in gross proceeds from Oaktree Capital Management and the Ishbia family. The transaction includes a rights offering to distribute up to 200 million shares of Class A Common Stock for at least $400 million in aggregate proceeds, fully backstopped by the Ishbia Purchaser.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Tarsus Pharmaceuticals completed a private placement (PIPE) of approximately $125.0 million, consisting of 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase 133,625 additional shares at $0.0001 per share. The unregistered securities were sold to qualified institutional buyers and accredited investors under Section 4(a)(2) of the Securities Act, with registration rights to be granted under a Registration Rights Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The company issued approximately $12.2 million in unregistered equity securities across two separate transactions in June and July 2026, across multiple share classes (E, AA, I-S, F, FF, A) to investors and as compensation to Sculptor Advisors LLC and independent directors, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
North Haven Net REIT sold 2,790,195 common shares for approximately $58.3 million in an unregistered private offering under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance that raises capital through unregistered securities sales, materially affecting shareholder ownership and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
Franklin BSP Real Estate Debt, Inc. sold 339,562.25 shares of multiple classes of common stock (Class G, Class G-D, Class G-S, and Class I) on August 3, 2026, for aggregate consideration of $8,413,717 in a continuous private offering exempt from registration under Section 4(a)(2) and Regulation D. This is a classic unregistered equity issuance disclosed under Item 3.02, materially dilutive to existing shareholders and a significant capital raise for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 8.01
Prologis entered into an underwriting agreement on August 4, 2026 for a registered public offering of 15,000,000 shares of common stock, generating approximately $2.1 billion in net proceeds (or $2.4 billion with the underwriters' over-allotment option). This is a material registered equity issuance that dilutes existing shareholders. The filing explicitly discloses the offering is expected to close on August 5, 2026, and the proceeds will be contributed to the Operating Partnership for general corporate purposes, including potential acquisitions such as SEGRO plc.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-05
Item 1.01
Twist Bioscience completed a registered public offering of 3,125,000 shares of common stock at $96.00 per share, with underwriters exercising their option to purchase an additional 468,750 shares, generating approximately $327.1 million in net proceeds. The offering was upsized from an initially proposed $250.0 million and will dilute existing shareholders while providing capital for R&D, manufacturing expansion, and general corporate purposes.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-05
NetClass Technology issued 100,000 Class B Ordinary Shares to Dragonsoft Holding Limited (controlled by CEO Dr. Jianbiao Dai) on August 5, 2026, pursuant to a securities purchase agreement dated August 1, 2026. The issuance was made under Section 4(a)(2) exemption, indicating an unregistered private placement. Post-issuance, the Buyer holds 100% of Class B shares representing 77.93% of total voting power, constituting a material dilutive equity issuance to an insider-controlled entity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 3.02
Campbell Fund Trust sold unregistered Units of Beneficial Interest totaling approximately $5.18 million across three series (A, D, and W) on July 31, 2026, in reliance on Section 4(2) of the Securities Act and Regulation D. This is a classic private placement of equity securities exempt from registration, which dilutes existing unitholders and represents a material capital-raising event for the fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
The Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC authorizing the issuance and sale of up to $200.0 million in shares of Common Stock through an at-the-market offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 1.01
ZW Data Action Technologies Inc. entered into five Securities Purchase Agreements on July 30, 2026, to sell an aggregate of 1,000,000 shares of common stock at $1.45 per share for a total of $1,450,000 in a private placement of unregistered equity securities to accredited investors under Section 4(a)(2) and Regulations D and S. This unregistered issuance will dilute existing shareholders' ownership and materially affect the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 3.02
Mitesco issued approximately 11.1 million shares of unregistered restricted common stock across five tranches (gifts, software developer compensation, advisory agreement, consulting services, and board director compensation), increasing outstanding shares from approximately 36 million to 47 million—a 31% dilution. The securities are unregistered and may not be offered or sold absent registration or exemption.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-05
Item 8.01
The Company completed a registered public offering of 1,086,957 shares of common stock on July 30, 2026, with an additional 260,869 option shares exercised and purchased on August 5, 2026, generating approximately $14.1 million in gross proceeds. This represents a material dilutive issuance of registered equity securities under a Form S-3 registration statement, with proceeds earmarked for capital expenditures, working capital, and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-08-05
Item 1.01
FTC Solar entered into a Lincoln Park Capital Purchase Agreement on August 4, 2026, establishing an equity line of credit for up to $20 million of common stock and issuing 60,145 commitment shares as consideration. The company will issue additional shares under the ELOC arrangement in reliance on Section 4(a)(2) and Rule 506(b) exemptions, providing flexible equity financing typical of small- to mid-cap companies.
View raw filing on EDGAR →